弥漫性胶质瘤中CD37的临床特征、预后意义及免疫异质性
The clinical features, prognostic significance, and immune heterogeneity of CD37 in diffuse gliomas.
作者信息
Yan Xuejun, Zhou Quanwei, Zhu Hecheng, Liu Weidong, Xu Hongjuan, Yin Wen, Zhao Ming, Jiang Xingjun, Ren Caiping
机构信息
Cancer Research Institute, Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China.
The NHC Key Laboratory of Carcinogenesis and The Key Laboratory of Carcinogenesis and Cancer Invasion of the Chinese Ministry of Education, School of Basic Medical Science, Central South University, Changsha 410008, China.
出版信息
iScience. 2021 Oct 9;24(11):103249. doi: 10.1016/j.isci.2021.103249. eCollection 2021 Nov 19.
Diffuse glioma is the most prevalent and malignant brain tumor. The function and significance of CD37 in diffuse gliomas remain largely unknown. Here, we showed CD37 was abnormally expressed in diverse cancers, especially glioma by pan-cancer differential expression analysis. In addition, we found CD37 was upregulated in higher grade and IDH or IDH1-wildtype gliomas, which was further validated by qPCR and IHC. Survival analysis revealed CD37 served as an independent indicator for unfavorable prognosis of patients with diffuse gliomas. Functional enrichment analysis revealed CD37 was associated with immunological processes. Moreover, immune infiltration analyses suggested gliomas with high-expression CD37 had greater infiltration of M2 macrophages and neutrophils, and lower NK cell abundance. CD37 was closely correlated to immune checkpoint molecules, including CD276, CD80, CD86, and PD-L2. Our results indicated CD37 is an independent prognostic factor and plays an immunosuppressive role in diffuse gliomas. Targeting CD37 could be a promising immunotherapeutic strategy for diffuse gliomas.
弥漫性胶质瘤是最常见且恶性程度最高的脑肿瘤。CD37在弥漫性胶质瘤中的功能和意义在很大程度上仍不清楚。在此，我们通过泛癌差异表达分析表明，CD37在多种癌症中异常表达，尤其是在胶质瘤中。此外，我们发现CD37在高级别以及异柠檬酸脱氢酶（IDH）或IDH1野生型胶质瘤中上调，这通过定量聚合酶链反应（qPCR）和免疫组化（IHC）进一步得到验证。生存分析显示，CD37是弥漫性胶质瘤患者预后不良的独立指标。功能富集分析表明，CD37与免疫过程相关。此外，免疫浸润分析表明，高表达CD37的胶质瘤有更多的M2巨噬细胞和中性粒细胞浸润，自然杀伤（NK）细胞丰度较低。CD37与免疫检查点分子密切相关，包括CD276、CD80、CD86和程序性死亡配体2（PD-L2）。我们的结果表明，CD37是一个独立的预后因素，在弥漫性胶质瘤中发挥免疫抑制作用。靶向CD37可能是弥漫性胶质瘤一种有前景的免疫治疗策略。
Zotero 插件